Related Experiment Video
Updated: Jun 20, 2025

Author Spotlight: Advancing Antiviral Strategies Through Novel Immunocapture and Mass Spectrometry Techniques
Published on: January 12, 2024
Unveiling a Comprehensive Multi-epitope Subunit Vaccine Strategy Against Salmonella subsp. enterica: Bridging Core,
Yamini Chand1, Tanvi Jain1, Sachidanand Singh2
1Faculty of Biotechnology, Institute of Biosciences and Technology, Shri Ramswaroop Memorial University, Lucknow-Deva Road, Barabanki, 225003, Uttar Pradesh, India.
A novel computational approach developed a universal Salmonella subsp. enterica (SE) vaccine candidate, SE-MESVC-4. This potential vaccine shows promise for inducing both humoral and cellular immunity against SE infections.
Area of Science:
- Computational vaccinology
- Infectious disease research
- Immunoinformatics
Background:
- Salmonella subsp. enterica (SE) infections pose a significant global health burden.
- Existing SE vaccines have limitations in strain specificity, efficacy, and accessibility, particularly for young children and low-income populations.
Purpose of the Study:
- To develop a universal SE vaccine using a computational approach.
- To identify potential drug targets for SE infections.
Main Methods:
- Integrated core proteomics, subtractive proteomics, and immunoinformatics.
- Designed multi-epitope-based subunit vaccine constructs (MESVCs) using reverse vaccinology.
- Evaluated MESVCs for antigenicity, immunogenicity, toxicity, and physicochemical properties.
- Performed molecular docking and dynamics simulations with MHC and TLR4 receptors.
- Conducted in silico immune simulations.
Main Results:
- Identified 1964 conserved SE proteins, 9 potential vaccine candidates, and 41 drug targets.
- Designed four MESVCs; SE-MESVC-4 demonstrated the most promising binding affinity and stability with TLR4/MD2.
- In silico simulations predicted SE-MESVC-4's ability to induce both humoral and cellular immune responses.
Conclusions:
- SE-MESVC-4 is a potential candidate for a universal SE vaccine.
- Further experimental validation is required to confirm the immunogenicity and efficacy of SE-MESVC-4.
More Related Videos
09:43Subtyping of Campylobacter jejuni ssp. doylei Isolates Using Mass Spectrometry-based PhyloProteomics MSPP
Published on: October 30, 2016
00:10Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation
Published on: August 21, 2019